Clinical trials, biomarkers, microbiome, genetics, AI, basic science, and emerging IBD research.
Page 23 of 65 · 3103 articles
A blood biomarker that reliably indicates mucosal healing could reduce reliance on colonoscopy, help monitor disease activity more frequently, and better guide treatment decisions in UC.
This review collects evidence about treatments specifically studied in monogenic forms of IBD, which can point toward precision, gene- or pathway-targeted therapies for people whose disease is caused by a single genetic...
The work identifies factors that predict loss of response to infliximab and suggests maintenance drug levels are the strongest predictor, which could influence monitoring strategies for people with Crohn's disease on...
Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from Digestive and liver...
The study reveals a new mechano-chemical mechanism regulating gut-homing integrin α4β7, which may help explain how lymphocytes home to inflamed intestines in IBD and points to a possible target for anti-adhesion...
Targeting IL‑1 is a promising route to reduce gut inflammation in IBD, but existing IL‑1 drugs face delivery and stability challenges. Nanocarriers could improve how these agents reach inflamed intestinal tissue, which...
Serum LRG1 is a candidate blood biomarker for mucosal inflammation in UC, but anti-TNF drugs may suppress its levels and cause false-negative results. This affects noninvasive monitoring and decisions based on LRG1...
Researchers identified COPZ1 as a shared ferroptosis-related hub gene in Crohn’s disease, ulcerative colitis, and periodontitis, which could point to a new molecular pathway linking gut and oral inflammation and a...
The mucus layer and goblet cells are central to colonic barrier function; understanding goblet cell diversity and plasticity could point to new ways to restore the mucus barrier in UC and improve disease control.
Surgeons and other clinicians managing IBD patients need to understand current biologic and immunomodulator options, their risks, and implications for surgical timing and perioperative care.
The work highlights a widespread tire-derived contaminant (6PPDQ) that may worsen colitis in a mouse model by disturbing key molecular pathways; this raises questions about whether environmental pollutants could...
The study suggests a common plant compound (oxalate) may build up in the intestines of people with IBD because transporter proteins are reduced, potentially worsening inflammation. If confirmed, this could influence...
The study links a common dietary flavonoid, epicatechin, to restoration of a protective ILC3 subset and mucosal repair in mouse colitis via a defined molecular pathway. This could point to new therapeutic targets for...
A single agent that both highlights inflamed colon tissue on MRI and delivers anti-inflammatory therapy could improve how ulcerative colitis is monitored and treated, reducing reliance on metal contrast agents.
This paper links preclinical models and a short Phase 2a trial to show a candidate SIK2/SIK3 inhibitor (GLPG3970) produced anti-inflammatory and mucus-restoring signatures in IBD tissues. If findings hold in larger...
Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease and Research and clinical trials. The original article is from Saudi journal of gastroenterology :...
Based on the title and source metadata, this appears to be a systematic review or meta analysis related to Inflammatory bowel disease and Research and clinical trials. The original article is from Saudi journal of...
Imaging found increased visceral fat in children with Crohn's despite normal BMI, which could reveal inflammation-related risk not apparent from weight alone. Visceral adiposity was linked to markers of inflammation and...
If validated, serum osmolality — a routine, low-cost blood measure — could become an additional marker to help identify IBD in certain hospitalized patients with anxiety. This could aid research and possibly improve...
Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Microbiome. The original article is from Pakistan Veterinary Journal.
This study identifies a specific gut microbe (Turicimonas muris) and an immune pathway link by which a high-fat diet reduced experimental colitis severity in mice, suggesting diet–microbiome interactions can strongly...
Based on the title and source metadata, this appears to be a basic science related to Inflammatory bowel disease and Research and clinical trials. The original article is from Inflammation.
Patients with ulcerative colitis may develop advanced neoplasia after seemingly complete endoscopic removal of dysplasia. Detecting genomic alterations in adjacent, histologically normal margins could identify...
Depression and GI diseases often co-occur; knowing which tends to appear first — and that this varies by subtype — can help clinicians prioritize screening and integrated care.
The study identifies specific small molecules and polysaccharide features in Atractylodes macrocephala that correlated with reduced inflammation in a mouse model of ulcerative colitis, which could guide future...
Cure8 found this source from Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, but the page could not be read reliably yet....
Genetic variation in MYO9B has been linked to Crohn’s disease, ulcerative colitis, and celiac disease. This study suggests a plausible epithelial-cell mechanism — altered microvilli and RhoA signaling — that could help...
Monogenic causes (especially IL-10RA mutations) are common in infant-onset IBD and are linked to more severe disease and higher mortality; early genetic testing and consideration of HSCT may change prognosis.
A non-invasive test (intestinal ultrasound) that predicts whether patients stay on biologic therapy could reduce the need for frequent endoscopy and help guide monitoring decisions.
This study describes a programmable, inflammation-responsive engineered probiotic aimed at targeting IBD flares by sensing calprotectin and delivering antioxidant and epithelial-protective factors — a concept that could...
This study suggests that cumulative infliximab exposure over time (AUC) — not just trough levels — may predict infection risk in people with IBD. That could affect how clinicians use therapeutic drug monitoring to...
A blood biomarker (OSM) that tracks microscopic inflammation could help detect residual disease activity that fecal calprotectin and routine clinical scores miss. That matters because histological inflammation predicts...
The paper provides genetic evidence that acute pancreatitis and Crohn’s disease share polygenic risk and converge on immune and inflammatory pathways; this may explain some observed comorbidity and points to biological...
Knowing how IBD burden has changed over time and varies across states helps patients, clinicians, and health systems anticipate needs for diagnosis, specialized care, and resource planning. Rising Crohn’s burden in some...
Family history of CRC raises an individual’s absolute CRC risk whether or not they have IBD, and people with IBD who have multiple first‑degree relatives with CRC appear to have the largest increase in absolute risk....
IBD patients and clinicians may see more treatment options in the future if Lilly’s pipeline programs (notably mirikizumab and oral α4β7 inhibitors) succeed.
The 5-year PROFILE follow-up is presented as strong evidence that early, effective therapy (in this case infliximab plus an immunomodulator) can change the long-term course of Crohn’s disease by lowering surgery rates...
Cure8 found this source from magzter.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. Open the original article for the...
The review directly compares randomized-trial evidence for JAK inhibitors in moderate-to-severe Crohn's disease and highlights which regimens (notably upadacitinib) showed the most consistent efficacy signals,...
People with suspected or known IBD and their clinicians want accurate, noninvasive tests to detect inflammation. This review suggests NGAL may be sensitive for identifying IBD but existing data are limited and uncertain,...
Non-invasive blood biomarkers that predict who will respond to therapy could help personalize treatment and avoid ineffective medications. This study identifies plasma miR-145 and miR-191 as potential predictors of...
The paper describes a new nanodelivery method that improves targeted delivery of 5‑ASA in preclinical models, which could eventually address limitations of oral mesalazine formulations for colonic inflammation.
If validated, a genetic marker (IL12B rs6887695) might help predict which patients are more likely to benefit from ustekinumab, potentially informing personalized treatment choices in IBD.
Children with newly diagnosed ulcerative colitis in this study commonly had reduced muscle mass (sarcopenia) at diagnosis, and the degree of muscle loss correlated with higher disease activity and inflammation....
If confirmed, starting anti‑TNF therapy (infliximab) early plus an immunomodulator may reduce surgeries, hospital admissions, and progression to complicated disease behavior over 5 years compared with a traditional...
This study suggests airborne, soil-associated microbes can change the gut microbiome and reduce colitis severity in mice — a possible explanation for lower ulcerative colitis rates in rural areas. If similar effects...
Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Nanomedicine.
If donor ethnicity or specific microbial/metabolite signatures influence FMT success, results could help identify optimal donors or develop targeted microbiota-based treatments for ulcerative colitis.
